LSX Congress USA 2026

The organizer billed LSX Congress USA as drawing 1,000+ senior attendees, 300+ investors and 180+ expert speakers. The agenda was scheduled to include 2,000+ 1:1 partnering meetings across 4 forums and workshops and 5 content streams.

LSX Congress USA 2026 was held at the Hynes Convention Center in Boston, USA.

LSX Congress USA connects biotech companies at different stages of growth with the investors and pharma partners who can help shape what comes next. The event was billed as drawing 1,000+ senior attendees and 300+ investors.

Confirmed 2026 speakers spanned pharma business development and alliance roles at AbbVie, Merck, Johnson & Johnson, Eli Lilly, GSK and Servier Pharmaceuticals. Investor-side speakers included Blackstone Life Sciences, BNP Paribas Asset Management and Casdin Capital.

It was most useful for biotech founders and executives raising capital or seeking pharma partners, since the facts cite 300+ investors, 2000+ one-to-one partnering meetings and speakers from AbbVie, Merck & Co., Eli Lilly, GSK, Blackstone Life Sciences and Casdin Capital. Bench scientists and academics looking for technical depth would have got less from it, because the audience was senior business development and investor heavy and the sponsor list was mostly law firms and advisers such as Latham & Watkins, Skadden and Ernst & Young.

Attendees at biotech investor and partnering congresses usually wear business casual to smart business attire, with suits or blazers common among bankers, lawyers and pharma executives, though open collars and no tie are typical. Boston in late September can be mild or cool, so a light jacket was sensible for walking around the convention center area.